Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ipecac is an emetic agent derived from the roots and rhizomes of the plant *Carapichea ipecacuanha* (formerly *Cephaelis ipecacuanha*), containing active alkaloids such as emetine and cephaeline. It was historically used to induce vomiting in cases of poisoning by irritating the gastric mucosa and stimulating the medullary chemoreceptor trigger zone in the brain. Ipecac was also used as an expectorant at lower doses. Its use has been largely discontinued due to safety concerns and lack of efficacy compared to alternatives like activated charcoal. The drug is inherently toxic in large or repeated doses, with risks including cardiotoxicity and aspiration pneumonia[1][3][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ipecac.